LIVERPOOL-based drug development company has announced it has discovered a potentially important new antibiotic to fight MRSA.
The AIM-listed company said it had reached pre-clinical development stage with a new anti-infective compound designed to tackle the MRSA bacterium that causes potentially lethal infections in humans.
A statement said: “The discovery is a significant milestone for Redx’s commercial partnership with the NHS, working with The Royal Liverpool and Broadgreen University Hospitals Trust. This is the third Redx program to identify a drug development candidate since the beginning of the year.”
See the article in full at TheBusinessDesk.com
